Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752792 | 0.78 | RPS6KA3 (0.47) | RPS6KA3GAAMAPTMAPK1HSD17B10 | |
| SCHEMBL14454806 | 0.75 | RPS6KA3 (0.44) | RPS6KA3GAAMAPTMAPK1HSD17B10 | |
| SCHEMBL14454801 | 0.71 | RPS6KA3 (0.41) | RPS6KA3 | |
| SCHEMBL3500620 | 0.71 | RPS6KA3 (0.41) | RPS6KA3GAAMAPTMAPK1HSD17B10 | |
| SCHEMBL3499091 | 0.67 | ALDH1A1 (0.50) | GAAMAPTMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL18548474 | 0.67 | RPS6KA3 (0.41) | RPS6KA3GAAMAPTMAPK1HSD17B10 | |
| SCHEMBL3498262 | 0.63 | TGFBR1 (0.46) | MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL3755970 | 0.61 | RPS6KA3 (1.00) | RPS6KA3GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL11450695 | 0.59 | SMN1; SMN2 (0.43) | RPS6KA3GAAMAPTMAPK1HSD17B10 | |
| SCHEMBL5036641 | 0.58 | RPS6KA3 (0.48) | RPS6KA3GAAMAPTMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | MAP4K2, MAP4K5, MAP4K3 | RPS6KA3 250/4885GAA 3105/4885MAPT 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.